Showing 28,681 - 28,700 results of 28,937 for search '"Gastroenterology"', query time: 0.21s Refine Results
  1. 28681
  2. 28682
  3. 28683
  4. 28684

    Clinical Significance of Mean Platelet Volume Combined with Neutrophil–Lymphocyte Ratio in Predicting the Therapeutic Effect of Splanchnic Neurolysis by Dai J, Han Y, Fang T, Shao H, Teng L, Zou H

    Published 2023-10-01
    “…Junzhu Dai,1,* Yuxiang Han,1,* Tianyi Fang,2 Hongxue Shao,1 Lei Teng,1 Huichao Zou1 1Department of Pain Medicine, Harbin Medical University Cancer Hospital, Harbin, People’s Republic of China; 2Department of Gastroenterological Surgery, Harbin Medical University Cancer Hospital, Harbin, People’s Republic of China*These authors contributed equally to this workCorrespondence: Huichao Zou, Department of Pain Medicine, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, 150081, People’s Republic of China, Email zouhuichao@hrbmu.edu.cnIntroduction: In most cases of pain related to abdominal tumors, increasing the dosage of analgesics still makes the pain difficult to alleviate. …”
    Get full text
    Article
  5. 28685

    Features of the blood cytokine profile in gastroesophageal reflux disease in schoolchildren with gastritis and family history of peptic ulcer by T. V. Polivanova, V. A. Vshivkov, T. N. Akhmetshin

    Published 2023-06-01
    “…In the course of a scientific study, 142 children with gastroenterological complaints aged 7-17 years were examined. …”
    Get full text
    Article
  6. 28686

    A randomized multicenter Phase II study of perioperative tiotropium intervention in gastric cancer patients with chronic obstructive pulmonary disease by Fushida S, Oyama K, Kaji M, Hirono Y, Kinoshita J, Tsukada T, Nezuka H, Nakano T, Noto M, Nishijima K, Fujimura T, Ohta T

    Published 2015-10-01
    “…Sachio Fushida,1,2 Katsunobu Oyama,1,2 Masahide Kaji,2 Yasuo Hirono,2 Jun Kinoshita,1,2 Tomoya Tsukada,1,2 Hideaki Nezuka,2 Tatsuo Nakano,2 Masahiro Noto,2 Koji Nishijima,2 Takashi Fujimura,2 Tetsuo Ohta1,2 1Department of Gastroenterological Surgery, Kanazawa University Hospital, 2Digestive Disease Support Organization (DDSO), Kanazawa, Japan Background: Tiotropium, a long-acting inhaled anticholinergic drug, has been widely used in the treatment of chronic obstructive pulmonary disease (COPD). …”
    Get full text
    Article
  7. 28687

    NOTCH1-Related Leukoencephalopathy: A Novel Variant and Literature Review by Stefania Della Vecchia, Alessandra Tessa, Rosa Pasquariello, Luis Seabra, Yanick J. Crow, Roberta Battini

    Published 2024-03-01
    “…By describing a standardised five-year follow-up in one case and reviewing the other patients described to date, we outline recommendations relating to monitoring in this illness, emphasising the importance of psychiatric and gastroenterological surveillance alongside neurological and neuropsychological management. …”
    Get full text
    Article
  8. 28688

    Factors Associated With Regorafenib Adherence With Metastatic Colorectal Cancer by Kawakami K, Wakatsuki T, Soejima A, Kobayashi K, Yokokawa T, Aoyama T, Suzuki K, Suenaga M, Yamaguchi K, Inoue A, Machida Y, Hama T

    Published 2019-10-01
    “…Kazuyoshi Kawakami,1 Takeru Wakatsuki,2 Azusa Soejima,1 Kazuo Kobayashi,1 Takashi Yokokawa,1 Takeshi Aoyama,1 Kenichi Suzuki,1 Mitsukuni Suenaga,2 Kensei Yamaguchi,2 Ayaka Inoue,3 Yoshiaki Machida,3 Toshihiro Hama1 1Department of Pharmacy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Koto-Ku, Tokyo 135-8550, Japan; 2Department of Gastroenterological Chemotherapy, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Koto-Ku, Tokyo 135-8550, Japan; 3Section for Practical Education, Hoshi University School of Pharmacy and Pharmaceutical Sciences, Shinagawa-Ku, Tokyo 142-8501, JapanCorrespondence: Kazuyoshi KawakamiThe Japanese Foundation for Cancer Research, Cancer Institute Hospital, Depatment of Pharmacy, 3-8-31 Ariake Koto-ku, Tokyo 135-8550, JapanEmail kazu.kawakami@jfcr.or.jpIntroduction: Regorafenib is an oral multikinase inhibitor for the treatment of metastatic colorectal cancer (mCRC). …”
    Get full text
    Article
  9. 28689

    Comparative analysis of efficacy and safety of various anti-tuberculosis therapy regimens in patients with MDR/XDR tuberculosis by E. P. Myshkova, T. I. Petrenko, T. A. Kolpakova

    Published 2022-06-01
    “…Adverse events (AE) caused by TB drugs in Group I were observed significantly more often versus Group II: gastroenterological adverse events (pχ2 = 0.05), cardiac adverse events (pTTP = 0.05), and endocrinological adverse events (pTTP = 0.05). …”
    Get full text
    Article
  10. 28690
  11. 28691
  12. 28692
  13. 28693
  14. 28694
  15. 28695
  16. 28696
  17. 28697
  18. 28698
  19. 28699
  20. 28700